The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Journal
Cancer research and treatment
Journal Volume
54
Journal Issue
2
Date Issued
2022-04
Author(s)
Huang, Yen-Hsiang
Hsu, Kuo-Hsuan
Chin, Chun-Shih
Tseng, Jeng-Sen
Yang, Tsung-Ying
Chen, Kun-Chieh
Chen, Jeremy J W
Chang, Gee-Chen
Abstract
The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients.
Subjects
Adenocarcinoma; Bevacizumab; ErbB receptors; Lung neoplasms; Tyrosine kinase inhibitor
SDGs
Type
journal article